Tradestie Institutional Equity Comparison Engine

MNOV vs ENTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENTX Overall Edge

ENTX Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MNOV counters with relative strength in Valuation. Fundamentally, MNOV trades at 8.5x Forward P/E with -1232.2% operating margin (+12.4% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
MNOV 8.5x vs ENTX N/M Fwd P/E
Growth & Margin Winner ENTX
Op Margin -1232.2% vs 0.0% ยท YoY +12.4% vs -100.0%
Momentum & Technical Winner ENTX
1Y -8.4% vs +24.7% ยท 52W Pos 3% vs 73%
Options & Structure Winner ENTX
UNCLASSIFIED (50th %ile IV) vs CONSOLIDATION (33rd %ile IV)
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
1M Return +9.44%
1Y Return +24.72%
Forward P/E N/M
Unified AI Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MNOV -8.39% ENTX +24.72% Spread: +33.11 pp (ENTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MNOV Revenue ENTX Revenue MNOV Op. Margin ENTX Op. Margin Margin Edge
FY2012 $0M N/A -1363.8% N/A MNOV
FY2020 N/A $0M N/A -3059.7% ENTX
FY2021 $0M $0M -253.0% -2139.6% MNOV
FY2022 N/A $0M N/A -9714.2% ENTX
FY2023 $0M N/A -990.0% N/A MNOV
FY2024 N/A $0M N/A -5295.6% ENTX
FY2025 $0M $0M -3242.5% -27450.0% MNOV

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MNOV (5) vs ENTX (4)
Institutional Metric MNOV ENTX Criterion Row Winner
Market Capitalization Scale $65.1M $571.2M Larger Scale ENTX
Trailing P/E Ratio Valuation 8.5x N/M Lower Multiple MNOV
Forward P/E Ratio Valuation 8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY) Growth +12.4% -100.0% Higher Growth MNOV
Operating Margin (TTM) Profitability -1232.2% 0.0% Higher Margin ENTX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -24.8% -20.3% Higher ROE ENTX
52-Week Range Position Momentum 3% ($1โ€“$4) 73% ($1โ€“$4) Stronger Trend ENTX
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 38% Vol 0.92ฮฒ ยท 53% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MNOV vs ENTX Buy Guide
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
83d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 33rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MNOV nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.